Pfizer Limited - Asset Resilience Ratio
Pfizer Limited (PFIZER) has an Asset Resilience Ratio of 61.18% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Pfizer Limited strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2026)
This chart shows how Pfizer Limited's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Pfizer Limited to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Pfizer Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Pfizer Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs30.11 Billion | 61.18% |
| Total Liquid Assets | Rs30.11 Billion | 61.18% |
Asset Resilience Insights
- Very High Liquidity: Pfizer Limited maintains exceptional liquid asset reserves at 61.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pfizer Limited Industry Peers by Asset Resilience Ratio
Compare Pfizer Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
NanJing Pharmaceutical Co Ltd
SHG:600713 |
Drug Manufacturers - General | 0.85% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 7.83% |
Annual Asset Resilience Ratio for Pfizer Limited (2005–2026)
The table below shows the annual Asset Resilience Ratio data for Pfizer Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 61.18% | Rs30.11 Billion ≈ $325.64 Million |
Rs49.22 Billion ≈ $532.28 Million |
+4.56pp |
| 2025-03-31 | 56.62% | Rs27.81 Billion ≈ $300.72 Million |
Rs49.11 Billion ≈ $531.12 Million |
+8.80pp |
| 2024-03-31 | 47.82% | Rs20.22 Billion ≈ $218.70 Million |
Rs42.29 Billion ≈ $457.33 Million |
+2.04pp |
| 2023-03-31 | 45.79% | Rs18.32 Billion ≈ $198.10 Million |
Rs40.01 Billion ≈ $432.66 Million |
+5.25pp |
| 2022-03-31 | 40.54% | Rs15.81 Billion ≈ $171.01 Million |
Rs39.01 Billion ≈ $421.83 Million |
+8.66pp |
| 2021-03-31 | 31.88% | Rs10.41 Billion ≈ $112.59 Million |
Rs32.66 Billion ≈ $353.19 Million |
-17.70pp |
| 2020-03-31 | 49.58% | Rs21.84 Billion ≈ $236.21 Million |
Rs44.05 Billion ≈ $476.43 Million |
+2.02pp |
| 2019-03-31 | 47.55% | Rs18.74 Billion ≈ $202.63 Million |
Rs39.40 Billion ≈ $426.09 Million |
+0.81pp |
| 2018-03-31 | 46.75% | Rs17.25 Billion ≈ $186.56 Million |
Rs36.90 Billion ≈ $399.06 Million |
+1.28pp |
| 2017-03-31 | 45.47% | Rs14.87 Billion ≈ $160.81 Million |
Rs32.71 Billion ≈ $353.71 Million |
+45.32pp |
| 2016-03-31 | 0.15% | Rs43.26 Million ≈ $467.81K |
Rs29.14 Billion ≈ $315.11 Million |
+0.15pp |
| 2012-03-31 | 0.00% | Rs500.00K ≈ $5.41K |
Rs15.76 Billion ≈ $170.49 Million |
-39.68pp |
| 2011-03-31 | 39.68% | Rs5.50 Billion ≈ $59.49 Million |
Rs13.86 Billion ≈ $149.92 Million |
+8.76pp |
| 2010-03-31 | 30.92% | Rs3.72 Billion ≈ $40.24 Million |
Rs12.03 Billion ≈ $130.14 Million |
+8.33pp |
| 2009-03-31 | 22.59% | Rs2.48 Billion ≈ $26.82 Million |
Rs10.98 Billion ≈ $118.71 Million |
-30.54pp |
| 2008-03-31 | 53.13% | Rs4.61 Billion ≈ $49.85 Million |
Rs8.67 Billion ≈ $93.81 Million |
+42.82pp |
| 2007-03-31 | 10.31% | Rs666.73 Million ≈ $7.21 Million |
Rs6.47 Billion ≈ $69.92 Million |
-1.16pp |
| 2006-03-31 | 11.47% | Rs660.82 Million ≈ $7.15 Million |
Rs5.76 Billion ≈ $62.30 Million |
-1.92pp |
| 2005-03-31 | 13.39% | Rs699.09 Million ≈ $7.56 Million |
Rs5.22 Billion ≈ $56.47 Million |
-- |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more